-
Top 50 global pharmaceutical companies and their best-selling drugs in 2021
Time of Update: 2021-08-16
The list is ranked based on the global sales revenue of prescription drugs of each pharmaceutical company in 2020, which more intuitively reflects the hard power of each company's pharmaceutical business .
This list focuses on the sales of prescription drugs by global pharmaceutical companies.
-
Inventory of new drugs approved and accepted by NMPA in the first half of 2021
Time of Update: 2021-08-16
. The approval of vedicitumumab broke the situation that there is no original domestic new drug in the ADC drug field, and filled the gap in the treatment of patients with HER2 overexpression gastric cancer.
The listing of this variety provides a new treatment option for adult patients with non-small cell lung cancer (NSCLC) .
-
New indication for AstraZeneca dovalizumab is about to be approved in China
Time of Update: 2021-08-16
According to the official website of China's National Food and Drug Administration, AstraZeneca's blockbuster PD-L1 inhibitor durvalumab injection (durvalumab, trade name: Imfinzi) has a new indication for the market.
-
South Africa approves emergency use of Coxing's new crown vaccine
Time of Update: 2021-08-16
On July 3, local time, the South African Health Products Regulatory Authority (SAHPRA) announced that it has approved the conditional emergency use of the new crown vaccine produced by China Kexing Company in South Africa .
-
Lansoprazole, ranitidine...another alliance starts drug procurement and reporting work
Time of Update: 2021-08-16
According to MRCLUB, on July 10, the Henan Provincial Medical Insurance Bureau announced the Henan-China Alliance’s "Notice on Filling in the Pre-purchasing Quantity of Drugs Procured in Centralized Purchases".
-
These "special" pharmacies cut prices by more than 50%
Time of Update: 2021-08-16
You can buy medicines that are reimbursed by medical insurance at a special outpatient pharmacy nearby .
In addition, 61 designated hospitals in Liuyang can also handle special outpatient services, realizing "dual-channel" purchase of medicines for outpatients of special diseases .
-
Aotai Biology, Kaitron Biology, and Oriental Biology win the case against gabapentin immunoassay product 337 investigation
Time of Update: 2021-08-16
"Science Innovation Board Daily" reported on the 3rd, on July 1, US time, the United States International Trade Commission (ITC) made a final ruling on the investigation of gabapentin immunoassay kit
-
Hunan Provincial Public Resources Trading Center issued an announcement on the price adjustment of some drugs on the Internet
Time of Update: 2021-08-16
The content of the announcement pointed out that, in accordance with the "Notice of the Hunan Provincial Public Resource Exchange Center of the Hunan Provincial Medical Security Bureau on Regulating the Purchasing of Drugs on the Internet", the price of some drugs on the Internet that enterprises apply to be adjusted is now publicized .
-
Current status of research and development of neuropathic pain drugs
Time of Update: 2021-08-16
Recently, the literature reported that the target KCNQ2/3/5 (Kv7) channel opener retigabine (RTG) can significantly reduce Neuronal excitability, and effective in a variety of pain models, the two-hole potassium channel subtype TREK1 (TWIK-related K+ channel 1) is the key target of morphine analgesia without opioid adverse reactions, which provides new opportunities for neuropathic pain Treatment strategies .
-
Luoxin Pharmaceutical: Lansoprazole for injection passed the consistency evaluation of generic drugs
Time of Update: 2021-08-16
According to IQVIA data, the global sales of lansoprazole for injection in 2020 will be 210 million U.
S. dollars (calculated at the ex-factory price), and the domestic sales amount in China will be 1.
-
Pharmacopoeia Commission: Publicize 9 draft drug standards
Time of Update: 2021-08-16
Contact: Wang Zhijun; Zeng YiPhone: 010-67079559; 010-67079553Email: wangzhijun@chp.
Contact: Wang Zhijun; Zeng YiPhone: 010-67079559; 010-67079553Email: wangzhijun@chp.
Contact: Wang Zhijun; Zeng YiPhone: 010-67079559; 010-67079553Email: wangzhijun@chp.
Contact: Wang Zhijun; Zeng YiPhone: 010-67079559; 010-67079553Email: wangzhijun@chp.
Contact: Wang Zhijun; Zeng YiPhone: 010-67079559; 010-67079553Email: wangzhijun@chp.
-
Drugs facing an important review decision by the U.S. FDA in July 2021
Time of Update: 2021-08-16
CompilenewbornIn the first half of this year, the US FDA approved a total of 27 innovative drugs, and three (Brexafemme, Aduhelm, Rylaze) were approved in June .
Although the advisory committee did not support the approval of the drug, the FDA finally granted approval .
-
Hengrui Medicine: HRS3658 for injection was approved for clinical trial of drugs
Time of Update: 2021-08-16
On June 24, Hengrui Pharmaceuticals announced that its subsidiary product HRS3658 for injection has obtained a drug clinical trial approval notice, and the product is intended to be used for the treat
-
Northeast Pharmaceutical Director Xu Zhixin resigns
Time of Update: 2021-08-16
Xu Zhixin applied to resign as a director of the company's eighth board of directors .
Xu Zhixin resigned, he did not hold any position in the company .
Xu Zhixin does not hold any company shares .
-
Amgen Carfilzomi is about to be approved in China
Time of Update: 2021-08-16
Carfilzomib (Kyprolis) is a proteasome inhibitor .
The proteasome can break down damaged or no longer needed proteins, and it plays an important role in the normal function and growth of cells .
-
Review of Ceftriaxone Sodium for Injection and Lansoprazole for Injection in Shanghai Pharmaceuticals
Time of Update: 2021-08-16
In May 2018, Shanghai Pharmaceutical Xinya submitted an application to the State Food and Drug Administration for the consistency evaluation of generic ceftriaxone sodium for injection and was accepted .
-
"Eight provinces and two districts" inter-provincial alliance's procurement results officially announced!
Time of Update: 2021-08-16
On the 9th, the "Eight Provinces and Two Districts" Joint Procurement Office announced the official selection results of the "Eight Provinces and Two Districts" inter-provincial alliance drug centralized procurement (purchasing number: HLJ-YPDL2021-1), and the plan announced on June 24 The results of the selection are consistent, as follows:The "Eight Provinces and Two Districts" include Heilongjiang, Shanxi, Inner Mongolia Autonomous Region, Liaoning, Jilin, Sichuan, Tibet, Hainan, Qinghai, and Guizhou.
-
Hisun Pharmaceutical's Class 1 new drug "Haibo Maibu Tablets" was approved for listing
Time of Update: 2021-08-16
For patients with atherosclerotic cardiovascular disease and other risk diseases, the target value has not reached the target value after conventional statin treatment In patients with hypercholesterolemia, on the basis of 10 mg atorvastatin as the background treatment, the dose of Hezemibu or atorvastatin was doubled, FAS set analysis, LDL-C Hezemibu was reduced by -16.
-
BeiGene tislelizumab's new indications for marketing applications are accepted in China
Time of Update: 2021-08-16
Today, BeiGene announced that the Center for Drug Evaluation (CDE) of the National Food and Drug Administration (NMPA) of China has accepted its anti-PD-1 antibody drug Bezean (tislelizumab injection) for the treatment of the past New indication marketing application (sBLA) for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed or become intolerable after receiving first-line standard chemotherapy .
-
my country's first original ADC new drug Rongchang Biological Vidicuzumab is planned to be included in breakthrough therapy
Time of Update: 2021-08-16
On June 9th, the State Food and Drug Administration issued an announcement on the approval of the listing of vedicitumumab for injection, which is applicable to HER2 overexpression locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) that has received at least two systemic chemotherapy ) Treatment of patients .
